Fujian Haixi New Drug Creation Co., Ltd.

Primary Objective: This study used Lercanidipine Hydrochloride Tablets (10 mg) from Fujian Haixi New Drug Creation Co., Ltd. as the test formulation. In accordance with relevant bioequivalence regulations, Lercanidipine Hydrochloride Tablets (10 mg, trade name: Zainingping®) from the original manufacturer, Recordati S.P.A., served as the reference formulation. The study evaluated the bioequivalence of the test and reference formulations after administration under fasting conditions. Secondary Objective: To investigate the safety of the test and reference formulations, Lercanidipine Hydrochloride Tablets (10 mg, trade name: Zainingping®), in healthy volunteers.

Main research purpose: This study uses Pinaverium Bromide Tablets (Specification: 50 mg) developed by Fujian Haixi New Drug Creation Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, Pinaverium Bromide Tablets (Specification: 50 mg, trade name: Dicetel) produced by ABBOTT LABORATORIES LIMITED and MYLAN LABORATORIES SAS as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary research purpose: To observe the safety of the test preparation Pinaverium Bromide Tablets and the reference preparation Pinaverium Bromide Tablets (trade name: Dicetel) in healthy subjects.